Skip to main content

Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer.

Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prové A, Maes H, Huget P, van Dam P, Vermeulen PB, Dirix LY

Publication: Br J Cancer (2010) • Vol 102 • Page 276-84PMID: 19953098View on PubMed

Purpose

The paper compared circulating tumor cell (CTC) detection rates of three different methods (CellSearch, AdnaTest, and real-time qRT–PCR) using peripheral blood of patients diagnosed with metastatic breast cancer as well as healthy volunteers.

Conclusion

Of the 76 patients diagnosed with metastatic breast cancer, 10% (8 patients) were positive for CTCs by all three methods. A CTC positive result was more likely using the real-time RT–PCR method (targeting either CK-19 and/or mammaglobin) than CellSearch (63 vs 36%, P=0.001) or the AdnaTest (61% vs 22%, P<0.001). While a positive CTC result using any of the three methods was not correlated with PR, HER2, or P53 status of the primary tumor, it was associated with high serum CA15.3 levels. Real-time qRT–PCR results for CTC markers were not associated with patient age, tumor progression, or ER status but CellSearch results were associated with patient age and tumor progression and a CTC positive AdnaTest result was correlated with ER status.

Studies (1)

Purpose

This study compared CTC detection rates of three different methods (CellSearch, AdnaTest, and real-time qRT–PCR) using peripheral blood of patients diagnosed with metastatic breast cancer and healthy volunteers. Blood was collected volunteers in CellSave tubes (10 mL), AdnaCollect blood collection tubes (2 x 5 mL), and EDTA tubes (9 mL) from 16 untreated cancer patients, 60 treated patients who received different cytostatic treatments mostly containing taxanes, vinorelbine, anthracyclines or capecitabine (N=40), endocrine therapy (N=17) or trastuzumab alone or in combination with other treatments (N=18) and 20 healthy. CellSave specimens were stored at room temperature and processed using the CellSearch Sytem within 72 h of collection. Blood collected into AdnaCollect tubes were immediately placed on ice, incubated with BreastSelect Beads, mRNA was recovered by magnetic separation using Olido(dT)-coated beads, and three breast cancer markers (Muc-1, HER2, and GA733-2) and a housekeeping gene (actin) were amplified by multiplex RT-PCR and visualized on a bioanalyzer. A specimen was classified as positive if a PCR fragment had a peak concentration ≥ of 0.30 ng/µl, while peaks with a concentration between 0.15–0.30 ng/ µl were classified as inconclusive, and a peak concentration <0.15 ng/ µl was classified as negative. EDTA blood was filtered for white blood cells with a LeukoLOCK filter, RNA was extracted using the LeukoLOCK system, analyzed by real-time quantitative multiplex RT-PCR for CK-19 and mammaglobin expression levels which were normalized to beta-actin (ACTB) and TATA-binding protein (TBP).

Summary of Findings

Moderate concordance was observed for blood specimens analyzed by CellSearch CTC and the AdnaTest (81%, P<0.001) and between AdnaTest results and specimens determined to be positive by CK-19 levels as detected by real-time RT-PCR (78%, P<0.0001). Fair agreement was observed between CellSearch and positive results determined by CK-19 (72%, P=0.002), by mammaglobin (60%, P=0.04), and by CK-19 and/or mammaglobin (57%, P=0.04). Slight correlation was observed between the AdnaTest and mammaglobin results (53%, P=0.37) and CK-19 and/or mammaglobin levels (50%, P=0.189). Patients were more likely to be positive (for either CK-19 and/or mammaglobin) by real-time RT–PCR than by CellSearch (63 vs 36%, P=0.001) or the AdnaTest (61% vs 22%, P<0.001) and a significant difference in positive results was observed between CellSearch and the AdnaTest (36 vs 22%, P=0.013). Eight patients (10%) were positive for all three methods.

With the CellSearch System, the median number of detectable CTCs in patients with progressive disease was significantly higher than in non-progressive patients (1 versus 0, P=0.004) and the number of detectable CTCs was positively correlated to both serum CA15.3 levels (P<0.001) and patient age (P=0.001); however, the presence of two or more CTCs was not correlated with ER, PR, HER2, or P53 expression within the primary tumor. With the AdnaTest, a CTC positive result (two positive blood samples) was positively correlated to high CA15.3 levels (P=0.001) and ER status of the primary tumor (P=0.02), but CTC results were not correlated to PR, HER2, or P53 status (P=0.53, P=0.17, and P=0.39, respectively), or tumor progression (P=0.22), nor was tumor progression associated with the number of CTC positive blood specimens (P=0.35). Real-time RT-PCR amplification of CK-19 and mammaglobin did not differ significantly between treated and untreated patient groups (P=0.87 and 0.91, respectively). Median levels of CK-19 and mammaglobin were significantly correlated (P=0.005) and both were correlated with CA15.3 levels (r=0.481, P<0.001 and r=0.386, P=0.001) but not with patient age. Of the 76 patient specimens, 20 (26%) patients were positive for CK-19, 41 (54%) for mammaglobin, 14 (18%) were positive for both, and 29 (38%) were negative for both. Forty-three percent of all patients (33/76) were positive for only one tumor marker (69% of untreated patients and 60% of treated patients, P=0.52). A positive real-time RT-PCR result for CK-19, mammaglobin, or either was not associated with tumor progression (P=0.19, 0.84, and 0.41, respectively), ER status (P=0.63, 0.47, and 0.55, respectively), PR status (P=0.57, 0.49, and 0.89, respectively), HER2 status (P=0.14, 0.74, and 0.40, respectively), or P53 status (P=0.11, 0.86, and 0.58, respectively).

  • Biospecimens

    FluidBlood
  • Preservation Types

    Other Preservative
  • Diagnoses

    NeoplasticCarcinoma
    Normal
  • Platforms

    Cell count/volumeFluorescent microscopy
    RNART-PCR
    RNAReal-time qRT-PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    CA15.3 serum levels
    ER status
    HER2 status
    PR status
    Tumor progression
    p53 status
    PreaquisitionPatient age
    Breast cancer patients: median age 62 years (range, 34–85) years
    Healthy volunteers: median age 39 years (range 25–54)
    Biospecimen Aliquots and ComponentsCell capture method
    Adna Breast Cancer Select/Detect
    CellSearch
    Real-time qRT-PCR SpecificTargeted nucleic acid
    Beta-actin (ACTB)
    CK-19
    Mammaglobin
    TATA-binding protein (TBP)
    RT-PCR SpecificTargeted nucleic acid
    GA733-2
    HER2
    Muc-1
    actin